Testing three-drug therapy versus cisplatin for recurrent NPC
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 70 years old.
- Your cancer is non-keratinizing nasopharyngeal cancer that has returned or spread.
- You haven’t had any whole-body (systemic) treatment for the recurrent/metastatic cancer yet.
- You can do usual activities fairly well (ECOG score 0 or 1) and have a life expectancy over 12 weeks.
- You have at least one measurable tumor on scans (RECIST 1.1).
- Your blood tests and organ function are in an acceptable range for trial treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial tests a new combination of three drugs (TPC, apatinib, and camrelizumab) against the standard two-drug regimen (GP plus camrelizumab) for people with high-risk nasopharyngeal carcinoma that has spread to neck lymph nodes. The goal is to see if the three-drug combination works better and is safe.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests a combination of two drugs—an investigational antibody that targets cancer cells (MRG003) and a chemotherapy pill (capecitabine)—along with an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back but hasn't spread. The goal is to see if this approach can help control the cancer.
This trial tests a combination of chemotherapy and immunotherapy (pembrolizumab) given before and after surgery for nasopharyngeal cancer that has come back locally. The goal is to see if this approach can control the cancer and improve outcomes for patients who can't have standard re-treatment.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.